A cohort analysis finds that risankizumab shows the lowest risk for serious infections compared to other systemic therapies ...
The codes must be fully implemented in acute care and ambulatory care settings to inform provider and public health responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results